Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Lunch & Poster Display session

41P - Pharmacotherapy preceding monocyte harvest interferes with the potency of monocyte-derived dendritic cell anticancer vaccine


12 Dec 2019


Lunch & Poster Display session


Eva Hlavackova


Annals of Oncology (2019) 30 (suppl_11): xi12-xi15. 10.1093/annonc/mdz448


E. Hlavackova1, K. Pilatova1, L. Fedorova1, P. Mudry2, P. Mazanek2, J. Sterba2, L. Zdrazilova Dubska1

Author affiliations

  • 1 Department Of Clinical Pharmacology Advanced Cell Immunotherapy Unit, Masaryk University Faculty of Medicine, 62500 - Brno/CZ
  • 2 Department Of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, 61300 - Brno/CZ


Abstract 41P


Refractory and relapsing sarcoma and high-risk neuroblastoma show poor prognoses. Monocyte-derived dendritic cell anticancer vaccine could extend the treatment modalities in these patients. Pharmacotherapy prior to mononuclear cell harvest may influence the quality of manufactured dendritic cell product.


In approved pediatric academic phase I/II clinical trial EudraCT 2014-003388-39 with primary safety endpoint an impact of preceding and concomitant therapy sixty days prior to mononuclear cell harvest on the manufactured anticancer vaccine quality characteristics in enrolled neuroblastoma and sarcoma subjects was statistically evaluated. The chemotherapeutic drugs, kinase inhibitors, biological therapeutics and growth factors were analysed.


Potency and quality control characteristic of thawed DCs included DC phenotype and 2-day cultivation DC phenotype, the production of IL-12 and IL-10 during 24-hour cultivation, allo-MLR and auto-MLR. Out of 47 enrolled subjects, pre-monocyte harvest treatment was evaluated in 23 (19 sarcoma, 4 neuroblastoma) subjects, of which 6 manufactured DC anticancer vaccines (5 sarcoma, 1 neuroblastoma) failed to pass quality control criteria. Dendritic cells from subjects pretreated with MTD-based dose of the alkylating agent (cyclophosphamide), topoisomerase I inhibitor (topotecan) and tyrosin kinase inhibitor (pazopanib) displayed impaired IL-12 production, depressed IL-12/IL-10 ratio, increased CD14 expression and poor T-cell stimulation in auto-MLR. Alkylating agent temozolomide (TMZ) together with topoisomerase I inhibitor (irinotecan) enabled the monocyte differentiation marked by decreased CD14 expression, however failed to display immunostimulatory properties with low CD80 expression and markedly decreased IL-12 production and IL-12/IL-10 ratio.


Pharmacotherapy should be understood as concomitant factor influencing the DC vaccine product quality outcome. Certain monocyte-interfering anti-cancer pharmacotherapy combinations prior to monocyte harvest were associated with impaired quality and potency of DC-based immunotherapy.

Clinical trial identification

EudraCT: 2014-003388-39.

Editorial acknowledgement

Legal entity responsible for the study

State Institute for Drug Control Czech Republic.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.